News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ophthotech Treats First Patient in a Phase I Trial of Monoclonal Antibody, Volociximab, for Age-Related Macular Degeneration


11/10/2008 11:36:49 AM

PRINCETON, NJ and NEW YORK, NY--(Marketwire - November 10, 2008) - Ophthotech Corp. announced today the treatment of its first patient with Volociximab, a monoclonal antibody targeting alpha5beta1 integrin, in a Phase I trial for the treatment of wet age-related macular degeneration (AMD). Ophthotech is a privately held biopharmaceutical company focused on developing ophthalmic therapies for both wet and dry AMD. Volociximab represents Ophthotech's third compound in clinical development. This Phase I trial will assess the safety, tolerability and pharmacokinetic profile of Volociximab.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES